Probiotic strains are not interchangeable. Within Lactobacillus alone, thousands of genetically distinct strains exist, each with a unique colonisation pattern and mechanism of action. Every strain in AEGIS™ was selected based on published peer reviewed evidence for a specific physiological target.

Clinical research consistently demonstrates a dose response relationship in probiotics. Biological activity occurs at specific CFU thresholds, unique to each strain. AEGIS™ delivers 64 billion CFU per daily serving, with each strain present at its documented active dose.

Growing probiotic bacteria at scale requires precision. Every variable — temperature, pH, oxygen levels, nutrient availability — directly determines whether the strains arrive alive and potent. Deviation at any point compromises strain viability and potency in the final product.

Following fermentation, cultures undergo freeze drying, a process that removes moisture while preserving cellular integrity. This renders the bacteria dormant and shelf stable without refrigeration, while maintaining full viability until the capsule is consumed and the cultures are reactivated in the gastrointestinal environment.

The AEGIS™ formula is built on a foundation of published scientific literature spanning gastroenterology, immunology, dermatology, and metabolic science. Every strain included in the formula has a documented research profile that can be independently reviewed. Science, not marketing, drives every formulation decision.

Peer reviewed research continues to characterise the gut microbiome as a central regulator of systemic health. The gut-brain axis, the gut-skin axis, and the gut-immune axis are all active areas of scientific investigation. The image above reflects what this research increasingly confirms — the gut communicates with virtually every system in the human body.

The stomach operates at a pH of 1.5 to 3.5. At this acidity, the majority of probiotic cultures in conventional capsule formats are non-viable before they reach the large intestine — the only site where colonisation and biological activity actually occur.

The outer capsule dissolves first, releasing XOS prebiotic fibre. XOS is resistant to mammalian digestive enzymes but selectively fermented by colonic Bifidobacterium and Lactobacillus, conditioning the gut environment before the probiotics arrive. The inner capsule then delivers 22 live strains to the large intestine intact.

The gut contains approximately 500 million neurons — more than the spinal cord. This network, known as the enteric nervous system, operates largely independently of the brain and communicates bidirectionally via the vagus nerve. Emerging research documents associations between microbiome composition and neurological outcomes including mood regulation, stress response, and cognitive function. The gut does not simply digest food. It actively participates in neurological signalling.

Gut bacteria are responsible for producing approximately 90% of the body's serotonin, along with GABA, dopamine precursors, and short chain fatty acids that cross the blood-brain barrier. The composition of the microbiome directly influences this production. A diverse, well-colonised microbiome produces a broader and more stable neurotransmitter profile than a depleted one.

The relationship between gut health and skin clarity is increasingly supported by peer reviewed literature. Dysbiosis — an imbalance in the gut microbiome — triggers systemic inflammatory responses that manifest visibly at the skin surface. Conditions including acne, eczema, rosacea, and general skin dullness have all been associated with measurable changes in microbiome composition in published research.

Both the gut and the skin function as barrier organs — their primary role is preventing unwanted substances from entering the body. Research indicates that compromise of the gut barrier, sometimes referred to as intestinal permeability, correlates with compromise of the skin barrier. Supporting the gut microbiome supports both systems simultaneously.

A diverse microbiome is a resilient microbiome. Research consistently associates higher microbial diversity with better metabolic health, stronger immune function, more stable mood, and lower rates of chronic disease. Conversely, low diversity microbiomes — common in individuals with poor dietary fibre intake, high antibiotic exposure, or chronic stress — are associated with dysbiosis and its systemic consequences.

Not all probiotic strains colonise the gut equally. Some strains are transient — they pass through without establishing residence, producing limited benefit. Others demonstrate documented colonisation capacity, establishing populations that persist and contribute to microbiome diversity over time. AEGIS™ selects strains with published colonisation evidence, not simply strains with high CFU counts.

The gut-associated lymphoid tissue — GALT — is the largest immunological organ in the human body. It lines the gastrointestinal tract and maintains continuous surveillance of the microbial environment. The composition of the microbiome directly educates and modulates GALT activity. A well-colonised microbiome trains the immune system toward appropriate tolerance and effective pathogen response. A depleted microbiome does the opposite.

Specific probiotic strains have documented immunomodulatory effects — the capacity to influence immune cell populations, cytokine production, and inflammatory response. This is not a general property of all probiotics. It is strain specific, dose dependent, and requires the probiotic to arrive at the gut alive. Strains that do not survive gastric transit cannot interact with GALT and produce no immunological effect.

ublished audits of commercial probiotic products have documented significant discrepancies between label claims and actual viable cell counts at point of consumption. CFU counts stated on labels reflect counts at time of manufacture — not at time of consumption, and certainly not after surviving gastric transit. The gap between what a label states and what actually reaches the gut can be substantial.

AEGIS™ addresses this gap at every stage. Freeze dried strains maintain viability through shelf life. The dual capsule architecture protects cultures through the gastric environment. XOS prebiotic fibre conditions the colonic environment before the probiotic arrives. The result is not a higher number on a label — it is a higher number of viable cultures reaching the site where they can actually colonise, produce short chain fatty acids, interact with GALT, and contribute to microbiome diversity.